A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder

The purpose of this study is to evaluate the efficacy; safety and tolerability of ASP8062 compared with placebo ASP8062 as add-on therapy to buprenorphine/naloxone.

Study Overview

• Status: Withdrawn
• Conditions: Opioid Use Disorder
• Intervention / Treatment: Drug: ASP8062; Drug: buprenorphine/naloxone; Drug: Placebo ASP8062

Detailed Description

The study will consist of the following periods: Screening Period (up to 56 days); Double-blind treatment period (12 weeks/ 85 days); a Buprenorphine/naloxone down-titration period (as determined by the participant in collaboration with the investigator) (14 days); and a Follow-up period (30 days post last dose ASP8062 or placebo ASP8062 for ASP8062 End of Treatment [EOT]).

• Study Type: Interventional
• Phase: Phase 2

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Participant has a diagnosis of moderate or severe opioid use disorder (OUD) according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Ed (DSM-5) using the Mini International Neuropsychiatric Interview (MINI) version 7.02.

• Participant is voluntarily seeking treatment for OUD, and is either:

  • Currently receiving medication-assisted treatment (MAT) (buprenorphine/naloxone maintenance dose equivalent to 16 mg/4 mg sublingual for >=28 days prior to screening) for OUD and considered clinically unstable, defined as: currently misusing opioids and has at least 4 positive urine drug screens during the Screening Period (including morphine and metabolites, diacetylmorphine [heroin], codeine, oxycodone, hydrocodone, hydromorphone, fentanyl and metabolites, meperidine, propoxyphene, tramadol, oxymorphone and methadone)
  • Is not currently receiving MAT for OUD, and has not received MAT (consistently for > 48 hours) within 60 days prior to screening, and is: willing to initiate buprenorphine/naloxone therapy; considered to be a good candidate for buprenorphine/naloxone treatment based on medical and psychosocial history; able to tolerate buprenorphine/naloxone at the required maintenance dose of 16 mg/4 mg during the 7 days prior to randomization; has a positive urine drug screen at the initial screening visit (Visit 1) (including morphine and metabolites, diacetylmorphine (heroin), codeine, oxycodone, hydrocodone, hydromorphone, fentanyl and metabolites, meperidine, propoxyphene, tramadol, oxymorphone and methadone).
• Participant does not have on-going opioid withdrawal symptoms (a score of < 11 on the Clinical Opioid Withdrawal Scale (COWS)) at the time of randomization (Day 1).
• Participant has a body mass index range of 18.5 to 45.0 kg/m^2, inclusive and weighs at least 50 kg at screening.
• Participant has stable living conditions.
• Participant agrees not to make significant changes to current non-medication therapy interventions (e.g., counseling, psychotherapy) in place at the time of Screening throughout the duration of the study.
• Participant agrees not to participate in another interventional study while participating in the present study; defined as from the time of informed consent form (ICF) signature until completion of the last study visit.

• Female participant is not pregnant and at least one of the following conditions apply:

  • Not a woman of childbearing potential (WOCBP)
  • WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 30 days after final investigational product (IP) administration.
• Female participant must agree not to breastfeed starting at screening and throughout the study period and for 30 days after final IP administration.
• Female participant must not donate ova starting at screening and throughout the study period and for 30 days after final IP administration.
• Male participant with female partner(s) of childbearing potential (including breastfeeding partner) must agree to use contraception throughout the treatment period and for 90 days after final IP administration.
• Male participant must not donate sperm starting at screening and throughout the study period and for 90 days after final IP administration.
• Male participant with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 90 days after final IP administration.

Exclusion Criteria:

• Participant has received any investigational therapy within 28 days or 5 half-lives, whichever is longer, prior to screening.
• Participant has a history of respiratory depression while on buprenorphine-based or other MAT for OUD.
• Participant has human immunodeficiency virus (HIV) per screening serology test.
• Participant has a positive hepatitis B surface antigen (HbsAg) or detectable hepatitis B DNA. Participants with negative HbsAg, positive hepatitis B core antibody (anti-HBc) and negative hepatitis B surface antibody (anti-HBs) are eligible if hepatitis B DNA is undetectable.
• Current diagnosis of chronic pain and currently treated with opioids other than buprenorphine or buprenorphine/naloxone.
• Current DSM-5 diagnosis of moderate to severe substance use disorder on any other psychoactive substances other than opioids, caffeine or nicotine (e.g., alcohol, sedatives) and the non-opioid substance use disorder(s) are considered primary or coprimary, causing current (last 30 days) significant impairment and/or would interfere with the efficacy and safety assessments.
• Participant has 2 or more positive urine drug screen (UDS) results for barbiturates or benzodiazepines during screening. (Day 1 eligibility will be based on a quick urine test conducted on-site, and not a sample sent to the central lab.)
• Participant has a known or suspected hypersensitivity to ASP8062, buprenorphine, naloxone or any components of the formulations used.
• Participant has previous exposure to ASP8062.
• Participant has a history of suicide attempt or suicidal behavior within 12 months prior to screening or has any suicidal ideation that meets criteria at a level of 4 or 5 by using the Columbia-Suicide Severity Rating Scale (C-SSRS) within 12 months prior to screening or who is at significant risk to commit suicide, as assessed at screening or at Day 1.
• Participant's prescription for buprenorphine/naloxone is unable to be filled at the pharmacy during Screening because they are already receiving an opioid based MAT.
• Participant has any clinically significant liver chemistry test result including aspartate aminotransferase [AST] or alanine aminotransferase [ALT] result > 3 times above the upper limit of normal (ULN), and total bilirubin [TBL] result > 1.5 times above the ULN at screening. These assessments may be repeated once, after a reasonable time period (but within the Screening Period).
• Participant has a mean pulse < 45 or > 110 beats per minute (unless above the upper bound of the range [> 110 beats per minute] deemed to be secondary to opioid withdrawal); resting systolic blood pressure > 140 mmHg or < 90 mmHg, and/or a resting diastolic blood pressure > 90 mmHg at screening (unless out of range blood pressure is deemed to be secondary to opioid withdrawal). These assessments may be repeated once after a reasonable time period (but within the Screening Period).
• Participant has a clinically significant abnormality on 12-lead electrocardiogram (ECG) at screening or at randomization (Day 1). If the ECG is abnormal an additional ECG can be carried out. If this also gives a clinically significant abnormal result the participant must be excluded.
• Participant has a history of chest pain or palpitation with either exertion or drug use, myocardial infarction, endocarditis (within 12 months of screening), unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias or torsade de pointes, structural heart disease or a family history of Long QT Syndrome.
• Participant has a clinically significant abnormality (e.g., severe respiratory insufficiency) in past medical history or at the screening visit that may place the participant at risk or interfere with the treatment outcomes.
• Participant has a mean corrected QT interval using Fridericia's formula (QTcF) > 450 msec (for male participants) and > 470 msec (for female participants) at screening or at randomization. If the mean QTcF exceeds the limits above, one additional triplicate ECG can be taken on Day 1.
• Participant has known kidney disease and a glomerular filtration rate (GFR) < 60 mL/min per meter squared at screening.
• Participant has evidence of any clinically significant, uncontrolled cardiovascular, gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, infectious, metabolic, urologic, pulmonary (including obstructive sleep apnea not controlled by a continuous positive airway pressure device), neurologic, dermatologic, psychiatric (other than moderate to severe OUD or other mild substance use disorders), renal and/or other major disease. Participants with mild, moderate or severe cocaine use disorder are not eligible.
• Participant has planned surgery during the study participation.
• Participant has an active malignancy or a history of malignancy (except for treated non melanoma skin cancer) within 5 years of screening.
• Participant's treatment for OUD was required by a court order, or participant's current incarceration or pending incarceration/legal action that could prohibit participation or compliance in the study.
• Participant is homeless or living in a shelter.
• Participant has manic-depressive illness or Major Depressive Disorder with psychotic features.
• Participant has clinically significant anemia or low hemoglobin (levels < 9 g/dL) at screening or donation of > 250 mL of blood or plasma within 30 days prior to providing informed consent.
• Participant is currently using protocol-specified prohibited medications and is unable to wash out or adjust their dosage.
• Participant has used any cytochrome P450 (CYP) 3A4 inhibitor (including most azole antifungals, macrolide antibiotics, protease inhibitors and antidepressants) or inducer (including phenobarbital, arbamazepine, phenytoin and rifampin) within 4 weeks prior to randomization.
• Participant has a negative lab test for buprenorphine and norbuprenorphine during screening (at any time prior to Day 1) for participants currently receiving treatment with buprenorphine/naloxone, or during the Run-in Period for participants newly initiating buprenorphine/naloxone treatment. The Day 1 collection will not be included in the eligibility assessment for either participant group.
• Participant has any condition which makes the participant unsuitable for study participation.
• Participant is an employee of the Astellas Group, the clinical research organization (CRO) involved or the investigator site personnel directly affiliated with this study and/or their immediate families (spouse, parent, child or sibling, whether biological or legally adopted).
• Participants with a positive urine drug screen for cocaine during Screening and/or a current diagnosis of mild, moderate or severe cocaine use disorder.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ASP8062 in combination with buprenorphine/naloxone; Participants will receive ASP8062 once daily at bedtime (QHS) and buprenorphine/naloxone once daily every morning (QAM) for 12 weeks.	Drug: ASP8062; oral; Drug: buprenorphine/naloxone; sublingual
Placebo Comparator: Placebo ASP8062 in combination with buprenorphine/naloxone; Participants will receive matching placebo once daily at bedtime (QHS) and buprenorphine/naloxone once daily every morning (QAM) for 12 weeks.	Drug: buprenorphine/naloxone; sublingual; Drug: Placebo ASP8062; oral

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of participants with >= 80% of urine samples negative for misuse of opioid drugs combined with self-reports negative for opioid use	Participants will undergo weekly assessments for misuse of opioid drugs through urine drug screening in combination with self-reports of opioid drug misuse. Percentage of participants with >= 80% of urine samples negative for misuse of opioid drugs combined with self reports negative for opioid use will be reported.	Up to 12 weeks
Number of participants with Adverse Events (AEs)	Adverse events (AEs) will be coded using medical dictionary for regulatory activities (MedDRA). An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study Investigational Product (IP) and other study treatments, whether or not considered related to the study IP and other study treatments. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study IP and other study treatments. This includes events related to the comparator and events related to the (study) procedures. An AE is considered "serious" if, the event: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or other medically important event.	Up to 16 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with laboratory value abnormalities and/or adverse events (AEs)	Number of participants with potentially clinically significant laboratory values.	Up to 16 weeks
The cumulative distribution function (CDF) of the percentage of urine samples negative for misuse of opioid drugs combined with self-reports negative for opioid use	Participants will undergo weekly assessments for misuse of opioid drugs through urine drug screening in combination with self-reports of opioid drug misuse. The cumulative distribution function (CDF) of the percentage of urine samples negative for misuse of opioid drugs combined with self-reports negative for opioid use will be reported.	Up to 12 weeks
Percentage of participants continuously abstinent from misuse of opioid drugs as assessed by urine samples and self-reports negative for opioid use	Participants will undergo weekly assessments for misuse of opioid drugs through urine drug screening in combination with self-reports of opioid drug misuse. Percentage of participants continuously abstinent from misuse of opioid drugs as assessed by urine samples and self-reports negative for opioid use will be reported.	Up to 12 weeks
Total number of visits of abstinence from misuse of opioid drugs as assessed by urine samples and self-reports negative for opioid use	Participants will undergo weekly assessments for misuse of opioid drugs through urine drug screening in combination with self-reports of opioid drug misuse. Total number of visits of abstinence from misuse of opioid drugs will be reported.	Up to 12 weeks
Number of participants with vital sign abnormalities and/or adverse events (AEs)	Number of participants with potentially clinically significant vital sign values.	Up to 16 weeks
Change from baseline in blood oxygen saturation (SpO2)	The blood oxygen saturation (SpO2) will be measured using a pulse oximeter placed on the participant's fingertip. Number of participants with low SpO2 levels will be reported.	Baseline and up to 16 weeks
Number of participants with Routine 12-lead electrocardiogram (ECG) abnormalities and/or adverse events (AEs)	Number of participants with potentially clinically significant Routine 12-lead ECG values.	Up to 16 weeks
Number of participants with suicidal ideation and/or suicidal behavior as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)	The Columbia-Suicide Severity Rating Scale (C-SSRS) is a clinician administered assessment tool that evaluates suicidal ideation and behavior. Number of participants that have an affirmative response provided to the 5 items for suicidal ideation (1. Wish to be dead, 2. Non-specific active suicidal thoughts, 3. Active suicidal ideation with any methods (not plan) without intent to act, 4. Active suicidal ideation with some intent to act, without specific plan, 5. Active suicidal ideation with specific plan and intent) and/or to the 5 items for suicidal behavior (1. Preparatory acts or behavior, 2. Aborted attempt, 3. Interrupted attempt, 4. Actual attempt, 5. Completed suicide) will be reported.	Up to 16 weeks
Overall mortality (including opioid overdose mortality)	The number of participants for overall mortality and mortality due to opioid overdose will be summarized by treatment group.	Up to 16 weeks

Collaborators and Investigators

• Sponsor: Astellas Pharma Global Development, Inc.
• Investigators: Study Director: Executive Medical Director, Astellas Pharma Global Development, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): November 8, 2021
• Primary Completion (Estimated): February 28, 2023
• Study Completion (Estimated): February 28, 2023

Study Registration Dates

• First Submitted: September 21, 2021
• First Submitted That Met QC Criteria: September 21, 2021
• First Posted (Actual): September 30, 2021

Study Record Updates

• Last Update Posted (Actual): November 6, 2024
• Last Update Submitted That Met QC Criteria: November 5, 2024
• Last Verified: October 1, 2024

More Information

Terms related to this study

• Keywords: Buprenorphine/Naloxone; ASP8062,; Opioid Use Disorder,; OUD,
• Additional Relevant MeSH Terms: Narcotic-Related Disorders; Mental Disorders; Chemically-Induced Disorders; Opioid-Related Disorders; Substance-Related Disorders; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Central Nervous System Depressants; Sensory System Agents; Analgesics; Analgesics, Opioid; Narcotics; Neurotransmitter Agents; GABA Modulators; GABA Agents; Narcotic Antagonists; Buprenorphine, Naloxone Drug Combination; ASP8062; Buprenorphine; Naloxone
• Other Study ID Numbers: 8062-CL-2221

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No